Supporting maternal health through the Riseup-PPD EU COST ACTION

The main goal of Riseup-PPD COST ACTION which started in April 2019 and will have a duration of 5 years, is to establish a Pan-European multidisciplinary network of researchers dedicated to the understanding of PPD, from its prevention and assessment to its treatment and global impact. Currently, 27 countries in the EU and beyond are part of this network including Albania, Israel, Turkey, Serbia, Bosnia, Norway, US and Brazil.

Riseup-PPD aims at filling gaps in PPD research, practice and social awareness by developing updated reviews, fostering research efforts on the standardisation of diagnostic criteria, the development of adequate screening tools and cost-effectiveness evaluation of prevention and treatment programs.

Finally, Riseup-PPD aims at developing a clinical protocol at EU level on how to treat PPD.

Additionally, the Action seeks to bridge multidisciplinary knowledge on the determinants of depressive symptoms in the peripartum period, and the mechanisms of action and change.

Finally, Riseup-PPD aims at developing a clinical protocol at EU level on how to treat PPD.

Currently available European estimates, show that PPD prevalence among mothers ranges from 4% to 38%, carrying several consequences for women, newborns-infants, and family systems, representing a socio-economic burden to society.

This Cost Action is aligned with MMM’s work on maternal health – we believe a mother’s mental health is a crucial topic that does not receive enough recognition and needs far more research.

For more information